An investment firm based in Singapore manages a fund which was raised entirely from its two founders; therefore, the firm invests more similarly to an angel fund rather than a typical venture capital fund. The firm seeks to invest in seed and series A rounds and is sector agnostic. The firm is interested in the life sciences and has made one investment thus far. The firm typically invests USD 100K-500K per company. The firm looks to invest in companies that are based in Asia and is actively seeking new investment opportunities.

The firm is sector agnostic and will invest opportunistically across the life sciences. Given the firm’s investment size, the firm generally does not invest in technologies that are capital intensive, i.e. drug development. However, the firm may consider co-investing in larger deals if the opportunity is attractive.

The firm places great emphasis on the management team and seeks a strong and experienced management team with prior achievements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Europe-based family of multi-stage venture capital funds invests in life science companies with a focus on niche indications with verified technology. The firm can allocate up to €10-15M per company and typically provides equity as well as debt financing. The firm generally acts as the lead or co-lead investor and is open to invest in syndicates. Currently, the firm seeks to invest in companies that are based in the European Union or US company that is open for an EU entity. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in innovative biotech therapeutics and pharmaceuticals with clear biology and verified technology. The firm is also interested in exceptional medical devices with a therapeutic application that is close to market or has generated some sales. The firm is opportunistic across the therapeutic subsectors but prefers products that target niche indications. Currently, the firm is more interested in oncology and orphan indications.

The firm requests a board seat in each portfolio company. The firm seeks a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical company based in Korea is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in CNS, infection, oncology, and immunology. The firm is also interested in other therapeutic areas that address unmet medical needs, including orphan diseases. The firm prefers assets from IND ready to late stage development. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; The firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm founded in 2014 and based in Silicon Valley invests in several fields including digital health, healthcare IT, and medical devices. The firm is currently raising its second fund, and typically invests an average of $300,000 per company, though this is dependent on the technology as the investment size may increase, particularly for hardware-based technology. The firm typically co-invests at present but is anticipating leading investments with the new fund. The firm typically makes 12-20 new investments per year, and focuses on companies based in North America (USA & Canada), though is open to looking at companies based on a global-level. Furthermore, the firm has a considerable value-add in supporting companies that may be interested in moving their markets to Asia by passing potential deals to the firm’s Shanghai office as its source of deal flow, and making the right introductions to Asian investors and/or distribution partners.

The firm is open to all subsectors of digital health, healthcare IT, diagnostics, mobile app healthcare technologies, and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage.

The firm does not have a particular management team requirement. The firm will help the company fill the team if necessary. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm with offices worldwide manages a $30 million seed-stage fund that seeks to invest in companies across a variety of industries, but it is most interested in A.I. technology and data-oriented companies. The investment is general in term of equity, but convertible loans will be considered as well. The typical investment size ranges from $250K to $500K and seeks 25 new investments per year. The fund generally invests in seed stage, but occasionally will invest in Series A and Series B rounds with co-investors. The firm will consider new opportunities around the globe.

In healthcare, the firm is currently looking for new investments in the medical technology and healthcare IT sectors. The firm will not consider investments in biotech therapeutics or drug development space. For medical devices, the firm considers Class 1&2 devices, depending on the opportunity, but it is most interested in low-risk devices that do not need FDA approval. In healthcare IT, the firm looks to invest in companies developing m-Health and e-Health. In terms of stage of development, the current fund focuses on seed-stage investments. Historically, the firm was active in companies targeting digital health and clinical data platform.

The firm looks to invest in private companies across the globe. The firm prefers to invest in companies with a strong and full management team with significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global alternative asset manager based in Shenzhen, China focuses on investments in the healthcare sector, currently focusing on acquisition or investment first and then acquisition. The firm is making new investments in venture stage companies from its 2015 vintage fund of US$50 million. Depending on the stage of the company, the firm can invest from several hundred thousand to tens of millions in companies with valuation under 1 billion RMB. The firm considers companies based in the US, Europe, Israel, and Asia with a focus on China-based businesses. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking to invest in medical devices that are novel and disruptive. The firm considers a broad range of medical devices with a focus on robotics, cardiovascular, cancer, diabetes, orthopedics, and ophthalmology. The firm typically invests in clinical stage projects but would consider devices at all stages.

Currently, the firm is only looking for privately held companies and typically requires board representation post-investment. The firm prefers to exit within 5 years, but can be flexible on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A California-based firm backed by strategic LPs closed its first fund in early 2016. The firm invests in early stage healthcare technologies that are strategically relevant to its LPs, which are major foreign corporations. The firm has a fund size of $75 million and is a multi-stage investor, interested in companies from the seed stage through to late-stage venture rounds. Investments therefore vary by stage, but the firm’s Series A investments may typically be of about $1-3 million. The firm generally prefers to act as a co-investor. The firm is focused on US-based opportunities.

The firm is interested in new technologies in digital health, medical devices, diagnostics, and therapeutics. The firm’s primary focus is on the intersection between data and biotech, diagnostics and medical devices, with microfluidics, connected devices, digitization, and automation being areas of high interest. For therapeutics, the firm generally does not invest in single-asset companies; therapeutic platform technologies that have the potential to create multiple ‘shots on goal’ are preferred. The firm prefers to focus on patients for whom there is high unmet need and no currently adequate treatments; rare diseases are of high interest. The firm is a multi-stage investor, and is open to investing in assets as early as the preclinical or pre-prototype stage.

The firm seeks management teams that display knowledge of how to build a business out of a strong technology. The firm focuses on technologies that allow the firm’s LPs to provide a value-add in partnering, manufacturing or distribution; healthcare technologies involving sensors and materials science are high focus areas. The firm evaluates opportunities on a technical, clinical and leadership level; the firm then shares the results of their diligence with the company in order to help the company in their future efforts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com